Ritchie Lab - Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).

Bergmeijer, T. O., Reny, J.-L., Pakyz, R. E., Gong, L., Lewis, J. P., Kim, E.-Y., Aradi, D., Fernandez-Cadenas, I., Horenstein, R. B., Lee, M. T. M., Whaley, R. M., Montaner, J., Gensini, G. F., Cleator, J. H., Chang, K., Holmvang, L., Hochholzer, W., Roden, D. M., Winter, S., & Altman, R. B. (2018). Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). The American Heart Journal., 198, 152–159. https://doi.org/10.1016/j.ahj.2017.12.010